LumiraDx Limited
Industry
- Biotechnology
- In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Hematology, Coagulation
- Chemistry, Immunoassay
- Digital Health
- Disease Management
Latest on LumiraDx Limited
LumiraDx's time as an independent diagnostics company is coming to an end with a sale to Roche just over three years after it went public. On September 2021, LumiraDx went public on NASDAQ followin
Advanced rapid action diagnostics are beginning to permeate their way through health care because of new technology and improvements in manufacturing testing equipment at scale spurred by the COVID-19
This month, AbbVie gave iStar Medical an upfront cash payment to continue the development of its glaucoma devices, with the deal also granting AbbVie the option to purchase iSTAR outright for near
July was yet another bumper month for pharma, which saw France-based Sanofi ink a $2bn deal with Skyhawk Therapeutics to develop small molecule drugs for oncology and immunology. (Also see " Sanof